Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Cancer. 2004 Jan 12;90(1):1-7.

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

Author information

1
1Department of Medical Oncology, Erasmus University Medical Center, PO Box 2040, Rotterdam 3000 CA, The Netherlands. f.eskens@erasmusmc.nl

Abstract

Angiogenesis is crucial for tumour growth and the formation of metastases. Various classes of angiogenesis inhibitors that are each able to inhibit one of the various steps of this complex process can be distinguished. Results from clinical studies with these agents are summarised. In general, it has been shown that most angiogenesis inhibitors can be safely administered, but that tumour regressions are rare. Combining angiogenesis inhibitors with cytotoxic chemotherapy can enhance anticancer activity. Recently, some promising data with regard to clinical efficacy have been presented. While performing clinical studies with angiogenesis inhibitors, defining biological activity is crucial, but thus far no validated techniques are available. It is conceivable that in the near future various classes of angiogenesis inhibitors will be combined in an attempt to further improve antiangiogenic and anticancer activity.

PMID:
14710197
PMCID:
PMC2395335
DOI:
10.1038/sj.bjc.6601401
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center